Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First human tests begin for experimental obesity medication

NCT ID NCT07170319

Summary

This early-stage study is testing the safety of a new drug called IBI3032 in people who are overweight or have obesity. Researchers will give 79 participants multiple doses over 4 weeks to check for side effects and see how the body processes the medication. The main goal is to determine if the drug is safe enough for further testing, not to measure weight loss results.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • The Frist Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, 230000, China

Conditions

Explore the condition pages connected to this study.